



## AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference

March 3, 2025

MENLO PARK, Calif.--(BUSINESS WIRE)--Mar. 3, 2025-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Leerink Partners Global Healthcare Conference.

Details of the event are as follows:

Leerink Partners Global Healthcare Conference

Eric Easom, Co-Founder, Chairman, President and CEO, will provide a corporate overview on Wednesday, March 12, 2025 at 2:20 pm ET, and members of management will be available for 1X1 meetings.

A webcast of the presentation can be accessed on the Investors section of the AN2 Therapeutics website at [www.an2therapeutics.com](http://www.an2therapeutics.com). An archived replay will be available for at least 30 days following the presentation.

### About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, NTM, and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. For more information, please visit our website at [www.an2therapeutics.com](http://www.an2therapeutics.com).

View source version on [businesswire.com](http://businesswire.com): <https://www.businesswire.com/news/home/20250303805852/en/>

### COMPANY CONTACT:

Lucy O. Day  
Chief Financial Officer  
[l.day@an2therapeutics.com](mailto:l.day@an2therapeutics.com)

### INVESTOR AND MEDIA CONTACT:

Anne Bowdidge  
[ir@an2therapeutics.com](mailto:ir@an2therapeutics.com)

Source: AN2 Therapeutics, Inc.